GlassScriptPhysician profile
Ashley Brueshaber
NPI 1104166800
$2,739.36
in general payments reported to CMS, 2019-2025
28 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $42.05 · 2023: $953 · 2024: $824 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,566.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $286.88 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $253.97 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $213.73 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.29 | 2021-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $179.78 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $177.85 | 2021-2025 | Wegovy, Ozempic |
| Otsuka America Pharmaceutical, INC. | $175.43 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $170.91 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $163.31 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $161.59 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.29 | 2023-2024 | Xifaxan |
| Abbvie INC. | $79.71 | 2023-2024 | |
| Glaxosmithkline, LLC. | $77.95 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Xeris Pharmaceuticals, INC. | $63.50 | 2023-2025 | Gvoke Hypopen |
| Csl Behring | $62.01 | 2025 | Hizentra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.28 | 2023-2024 | Jardiance |
| Dexcom, INC. | $56.22 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $48.34 | 2023-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $40.39 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $38.07 | 2025 | Fanapt |
| Edwards Lifesciences Corporation | $33.93 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Krystal Biotech INC | $24.37 | 2025 | Vyjuvek |
| Biohaven Pharmaceutical Holding Company LTD. | $24.35 | 2022 | |
| Insulet Corporation | $21.83 | 2023 | Omnipod |
| Kyowa Kirin, INC. | $16.99 | 2025 | |
| Axsome Therapeutics, INC. | $15.90 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $12.11 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Brueshaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.